Log in

NYSEAMERICAN:BPMX - Biopharmx Stock Price, Forecast & News

$0.28
+0.01 (+3.64 %)
(As of 03/30/2020 07:06 AM ET)
Today's Range
$0.27
Now: $0.29
$0.29
50-Day Range
$0.31
MA: $0.35
$0.39
52-Week Range
$0.25
Now: $0.29
$2.70
Volume454,239 shs
Average Volume1.54 million shs
Market Capitalization$5.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Read More
Biopharmx logo

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BPMX
CUSIPN/A
CIKN/A
Phone+1-650-8895020

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$5.21 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.


Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Biopharmx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biopharmx.

When is Biopharmx's next earnings date?

Biopharmx is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Biopharmx.

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.08. View Biopharmx's earnings history.

When did Biopharmx's stock split? How did Biopharmx's stock split work?

Shares of Biopharmx reverse split on Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for BPMX?

1 analysts have issued 1 year target prices for Biopharmx's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biopharmx's stock price to reach $1.00 in the next year. This suggests a possible upside of 250.9% from the stock's current price. View analysts' price targets for Biopharmx.

Has Biopharmx been receiving favorable news coverage?

News headlines about BPMX stock have been trending somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutBiopharmx.

Who are some of Biopharmx's key competitors?

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

Who are Biopharmx's key executives?

Biopharmx's management team includes the following people:
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
  • Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

Who are Biopharmx's major shareholders?

Biopharmx's stock is owned by many different institutional and retail investors. Top institutional investors include Barclays PLC (0.86%) and Virtu Financial LLC (0.45%). Company insiders that own Biopharmx stock include Anja B Krammer, David S Tierney, Stephen Morlock and Vivo Capital Viii, Llc. View institutional ownership trends for Biopharmx.

Which major investors are selling Biopharmx stock?

BPMX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, and Virtu Financial LLC. View insider buying and selling activity for Biopharmx.

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $0.29.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $5.21 million. Biopharmx employs 17 workers across the globe. View additional information about Biopharmx.

What is Biopharmx's official website?

The official website for Biopharmx is http://www.biopharmx.com/.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  307 (Thanks for Voting!)
Underperform Votes:  193 (Thanks for Voting!)
Total Votes:  500
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel